Journal article
Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy
Abstract
OBJECTIVES: Pelareorep (reolysin), a Dearing strain of reovirus serotype 3, has demonstrated oncolytic activity as single agent and synergy with chemotherapy. We evaluated pelareorep, combined with standard second-line chemotherapy in patients with non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: This randomized phase II trial enrolled patients with advanced or metastatic NSCLC after first line chemotherapy. After a safety run-in, …
Authors
Bradbury PA; Morris DG; Nicholas G; Tu D; Tehfe M; Goffin JR; Shepherd FA; Gregg RW; Rothenstein J; Lee C
Journal
Lung Cancer, Vol. 120, , pp. 142–148
Publisher
Elsevier
Publication Date
June 2018
DOI
10.1016/j.lungcan.2018.03.005
ISSN
0169-5002
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCanadaCarcinoma, Non-Small-Cell LungCombined Modality TherapyDocetaxelDrug Resistance, NeoplasmFemaleHumansLung NeoplasmsMaleMammalian orthoreovirus 3Middle AgedOncolytic VirotherapyOncolytic VirusesPemetrexedRecurrenceReoviridae InfectionsSalvage TherapyYoung Adult